The University of Oxford, which is jointly developing the vaccine with AstraZeneca, told CNBC the participant’s death did not reveal any concerns about the trial’s safety.
“The independent review in addition to the Brazilian regulator have recommended that the trial should continue,” University of Oxford spokesperson Alexander Buxton told CNBC.
The news comes six weeks after a participant in AstraZeneca’s U.K. trial developed transverse myelitis, a neurological condition in which the spinal cord becomes inflamed. The drugmaker resumed the trial in the U.K. Sept. 12 after gaining approval from the Medicines Health Regulatory Authority, the country’s equivalent of the FDA, but has yet to continue the trial in the U.S.
More articles on pharmacy:
Kodak says it will make APIs despite insider-trading allegations
FDA advisory panel to publicly discuss COVID-19 vaccine approval process
Health policy experts urge US to release all COVID-19 vaccine clinical trial protocols
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
